147 related articles for article (PubMed ID: 31977312)
21. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
[TBL] [Abstract][Full Text] [Related]
22. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.
Macdonald FR; Peel JE; Jones HB; Mayers RM; Westgate L; Whaley JM; Poucher SM
Diabetes Obes Metab; 2010 Nov; 12(11):1004-12. PubMed ID: 20880347
[TBL] [Abstract][Full Text] [Related]
23. Early administration of dapagliflozin preserves pancreatic β-cell mass through a legacy effect in a mouse model of type 2 diabetes.
Kanno A; Asahara SI; Kawamura M; Furubayashi A; Tsuchiya S; Suzuki E; Takai T; Koyanagi-Kimura M; Matsuda T; Okada Y; Ogawa W; Kido Y
J Diabetes Investig; 2019 May; 10(3):577-590. PubMed ID: 30290061
[TBL] [Abstract][Full Text] [Related]
24. Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model.
Lee YK; Oh TJ; Lee JI; Choi BY; Cho HC; Jang HC; Choi SH
Eur J Pharmacol; 2023 Oct; 957():175946. PubMed ID: 37541370
[TBL] [Abstract][Full Text] [Related]
25. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
[TBL] [Abstract][Full Text] [Related]
26. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
[TBL] [Abstract][Full Text] [Related]
27. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Joubert M; Jagu B; Montaigne D; Marechal X; Tesse A; Ayer A; Dollet L; Le May C; Toumaniantz G; Manrique A; Charpentier F; Staels B; Magré J; Cariou B; Prieur X
Diabetes; 2017 Apr; 66(4):1030-1040. PubMed ID: 28052965
[TBL] [Abstract][Full Text] [Related]
28. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
29. Dapagliflozin: A Review in Type 1 Diabetes.
Paik J; Blair HA
Drugs; 2019 Nov; 79(17):1877-1884. PubMed ID: 31664708
[TBL] [Abstract][Full Text] [Related]
30. Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes.
Ramírez-Rodríguez AM; González-Ortiz M; Martínez-Abundis E
Exp Clin Endocrinol Diabetes; 2020 Aug; 128(8):506-511. PubMed ID: 30149417
[TBL] [Abstract][Full Text] [Related]
31. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet.
Xu L; Nagata N; Chen G; Nagashimada M; Zhuge F; Ni Y; Sakai Y; Kaneko S; Ota T
BMJ Open Diabetes Res Care; 2019; 7(1):e000783. PubMed ID: 31749970
[TBL] [Abstract][Full Text] [Related]
32. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
33. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
34. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak LO; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
Diabetes Obes Metab; 2018 Nov; 20(11):2617-2626. PubMed ID: 29923295
[TBL] [Abstract][Full Text] [Related]
35. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201
[TBL] [Abstract][Full Text] [Related]
36. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
Daniele G; Xiong J; Solis-Herrera C; Merovci A; Eldor R; Tripathy D; DeFronzo RA; Norton L; Abdul-Ghani M
Diabetes Care; 2016 Nov; 39(11):2036-2041. PubMed ID: 27561923
[TBL] [Abstract][Full Text] [Related]
37. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
Olgar Y; Turan B
Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
[TBL] [Abstract][Full Text] [Related]
38. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
39. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y; Bajaj M; Yang HC; Ye Y
Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
[TBL] [Abstract][Full Text] [Related]
40. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
Alatrach M; Laichuthai N; Martinez R; Agyin C; Ali AM; Al-Jobori H; Lavynenko O; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
Diabetes; 2020 Apr; 69(4):681-688. PubMed ID: 31915153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
